Akerman announced today that it is representing OPKO in its purchase of PROLOR, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins. The all-stock transaction is valued at approximately $480 million and is expected to complete during the second half of 2013. Mary Carroll, chair of Akerman Senterfitt’s Corporate Practice Group and shareholder Teddy Klinghoffer are serving as lead attorneys in the deal.
The merger agreement between OPKO and PROLOR comes a month after Akerman announced that it represented OPKO Health Inc. (OPKO) in its $290 million acquisition of Cytochroma Inc. and helped the company close a $175 million private offering.
Akerman is recognized by U.S. News – Best Lawyers as a leading U.S. law firm for Corporate, M&A, Private Equity, Securities/Capital Markets, and Securities Regulation Law. In addition, Akerman’s Corporate Practice Group is recognized by The Legal 500 within the National Firms – Middle Market category and is ranked #1 by Chambers USA for Corporate/M&A & Private Equity in Florida. Akerman’s Corporate Practice Group advises public and private companies, including private equity funds, in mergers & acquisitions, securities offerings, financings and other transactional matters, with a strong focus on the middle market.
